November 13, 2015 (ImedexCME) ImedexCME thorough video on the differences in CAR-T techniques.

April 25, 2017 (Medical News Today) The researchers call their approach "minimalist nanovaccine." It is a simple mixture of the tumor antigen (molecules that uniquely...

April 21, 2017 (HealthDay News) Achievements include more pediatric immunizations, cancer immunotherapy, genomic discoveries The next seven great achievements in pediatric research are presented in an...

Genetic Drivers of Cancerous Tumor Growth All cancers have a genetic basis and can occur sporadically or be inherited. The three main cancer-causing genes...

A Tumor: Defined When you hear the word tumor, you automatically think of cancer. But what really is a tumor? A tumor, or neoplasm, is...

Based on early clinical trial data, chimeric antigen receptor therapy (CAR-T) has been most successful in which population? A. Children with acute lymphocytic leukemia B....

February 10, 2017 (CURE e-magazine) Genetically engineering immune cells to treat cancers took another step forward after promising results from the phase 1 trial of Axicabtagene ciloleucel (KTE-C19), a CAR T-cell therapy for patients with refractory diffuse large B-cell lymphoma (DLBCL).

April 5, 2017 (Medical News Today) There has been slow progress in immunotherapy for solid cancers. However, a recent study using adoptive T cell transfer, had some success on ovarian cancer. In this mouse study, the engineered T cells significantly increased survival rates.

February 28, 2017 (STAT) Kite Pharma is racing to win approval of their CAR-T cancer therapy. They have posted strong results with their new drug, stating that more than one-third of lymphoma patients are in remission six months after one treatment.

February 26, 2016 (Discovery Medicine) Cancer is an ever-changing tissue that uses different strategies to grow and expand. One of these strategies is avoiding immunity.